[
  {
    "ts": null,
    "headline": "Is Amgen (AMGN) a Safe Bet for Income Investors in Cheap Quarterly Dividend Stocks?",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 11 Cheap Quarterly Dividend Stocks to Buy Right Now. Amgen Inc. (NASDAQ:AMGN), a leading biotechnology company, offers investors a strong and diverse portfolio. It has more than two dozen brands, including several blockbuster drugs that each bring in over $1 billion in annual sales. Amgen Inc. (NASDAQ:AMGN)’s medicines […]",
    "url": "https://finnhub.io/api/news?id=175a98d10545c6e2115342be1370a70bf5bc27cefc2eb949bdb5b7ea74be7f84",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758814600,
      "headline": "Is Amgen (AMGN) a Safe Bet for Income Investors in Cheap Quarterly Dividend Stocks?",
      "id": 136883135,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 11 Cheap Quarterly Dividend Stocks to Buy Right Now. Amgen Inc. (NASDAQ:AMGN), a leading biotechnology company, offers investors a strong and diverse portfolio. It has more than two dozen brands, including several blockbuster drugs that each bring in over $1 billion in annual sales. Amgen Inc. (NASDAQ:AMGN)’s medicines […]",
      "url": "https://finnhub.io/api/news?id=175a98d10545c6e2115342be1370a70bf5bc27cefc2eb949bdb5b7ea74be7f84"
    }
  },
  {
    "ts": null,
    "headline": "Dow falls 175 points on losses for Amgen, Nike shares",
    "summary": "Dow falls 175 points on losses for Amgen, Nike shares",
    "url": "https://finnhub.io/api/news?id=6855a510b8868ab107f880cc8faaf8b9948ba942ab8bb84b352392ae2c37b519",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758812580,
      "headline": "Dow falls 175 points on losses for Amgen, Nike shares",
      "id": 136920811,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Dow falls 175 points on losses for Amgen, Nike shares",
      "url": "https://finnhub.io/api/news?id=6855a510b8868ab107f880cc8faaf8b9948ba942ab8bb84b352392ae2c37b519"
    }
  },
  {
    "ts": null,
    "headline": "Dow down 311 points on losses for shares of Nike, Amgen",
    "summary": "Dow down 311 points on losses for shares of Nike, Amgen",
    "url": "https://finnhub.io/api/news?id=aedca9afb9d4415a8f487174aaa61e100f6bc2d7907ddaa478b220957238799b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758808920,
      "headline": "Dow down 311 points on losses for shares of Nike, Amgen",
      "id": 136922032,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Dow down 311 points on losses for shares of Nike, Amgen",
      "url": "https://finnhub.io/api/news?id=aedca9afb9d4415a8f487174aaa61e100f6bc2d7907ddaa478b220957238799b"
    }
  },
  {
    "ts": null,
    "headline": "Dr. Robert Lenz Joins Unlearn as Strategic Advisor",
    "summary": "SAN FRANCISCO, September 25, 2025--Unlearn, a leader in AI solutions for clinical trials, welcomed Dr. Robert Lenz as a strategic advisor to advise Unlearn as they expand partnerships.",
    "url": "https://finnhub.io/api/news?id=b195de3ef66704423d604b693e99aef7c6be1a32010109bbaa87a01827e20c7f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758805200,
      "headline": "Dr. Robert Lenz Joins Unlearn as Strategic Advisor",
      "id": 136883010,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "SAN FRANCISCO, September 25, 2025--Unlearn, a leader in AI solutions for clinical trials, welcomed Dr. Robert Lenz as a strategic advisor to advise Unlearn as they expand partnerships.",
      "url": "https://finnhub.io/api/news?id=b195de3ef66704423d604b693e99aef7c6be1a32010109bbaa87a01827e20c7f"
    }
  },
  {
    "ts": null,
    "headline": "Amgen: MariTide's Progress, Reassessment Of The Horizon Acquisition",
    "summary": "Discover why Amgenâs portfolio and new drugs may drive long-term growth despite recent setbacks.",
    "url": "https://finnhub.io/api/news?id=14a5f6d213ec8cedcf6dc297f010787f97c3e86079a2a573e80528eb69fa9d47",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758780655,
      "headline": "Amgen: MariTide's Progress, Reassessment Of The Horizon Acquisition",
      "id": 136881615,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323875427/image_1323875427.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Discover why Amgenâs portfolio and new drugs may drive long-term growth despite recent setbacks.",
      "url": "https://finnhub.io/api/news?id=14a5f6d213ec8cedcf6dc297f010787f97c3e86079a2a573e80528eb69fa9d47"
    }
  }
]